JP2018517660A - 周皮細胞長鎖非コーディングｒｎａ - Google Patents

周皮細胞長鎖非コーディングｒｎａ Download PDF

Info

Publication number
JP2018517660A
JP2018517660A JP2017549195A JP2017549195A JP2018517660A JP 2018517660 A JP2018517660 A JP 2018517660A JP 2017549195 A JP2017549195 A JP 2017549195A JP 2017549195 A JP2017549195 A JP 2017549195A JP 2018517660 A JP2018517660 A JP 2018517660A
Authority
JP
Japan
Prior art keywords
lncrna
tykril
expression
inhibitor
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017549195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517660A5 (enExample
Inventor
ミハエル ツェハンドネル，クリストフ
ミハエル ツェハンドネル，クリストフ
ディメラー，ステファニー
ザイハー，アンドレアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of JP2018517660A publication Critical patent/JP2018517660A/ja
Publication of JP2018517660A5 publication Critical patent/JP2018517660A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017549195A 2015-03-20 2016-03-18 周皮細胞長鎖非コーディングｒｎａ Pending JP2018517660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102015003656.4 2015-03-20
DE102015003656 2015-03-20
PCT/EP2016/056013 WO2016150870A1 (en) 2015-03-20 2016-03-18 Pericyte long non-coding rnas

Publications (2)

Publication Number Publication Date
JP2018517660A true JP2018517660A (ja) 2018-07-05
JP2018517660A5 JP2018517660A5 (enExample) 2019-03-07

Family

ID=55586316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549195A Pending JP2018517660A (ja) 2015-03-20 2016-03-18 周皮細胞長鎖非コーディングｒｎａ

Country Status (5)

Country Link
US (1) US20180044672A1 (enExample)
EP (1) EP3271458A1 (enExample)
JP (1) JP2018517660A (enExample)
CA (1) CA2980385A1 (enExample)
WO (1) WO2016150870A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3042109T3 (en) * 2017-06-19 2025-11-18 Univ Lausanne Compositions for controlling cardiac fibrosis and remodeling
MX2021005507A (es) 2018-11-13 2021-06-18 Lipigon Pharmaceuticals Ab Oligonucleotidos de angptl4 que influyen en la regulacion del metabolismo de los acidos grasos.
CN109517049B (zh) * 2018-11-16 2021-04-13 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Linc00266-1多肽作为实体瘤标志物的应用
US10851376B2 (en) 2018-12-28 2020-12-01 The Florida International University Board Of Trustees Long noncoding RNAs in pulmonary airway inflammation
CN110699441A (zh) * 2019-06-18 2020-01-17 云南省玉溪市人民医院 一种检测骨质疏松症的生物标志物、该标志物的应用及检测方法
CN110403954B (zh) * 2019-07-19 2022-11-11 广东省实验动物监测所 LncRNA XLOC_110286的抑制剂在制备促进血管新生的药物中的应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111118143B (zh) * 2020-01-16 2020-09-15 西安市红会医院 检测及靶向rp11-754b17.1的试剂及其在关节炎中的应用
CN111560427A (zh) * 2020-05-19 2020-08-21 苏州大学附属儿童医院 lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用
WO2024102894A2 (en) * 2022-11-11 2024-05-16 The Regents Of The University Of California Methods for treating monge's disease
CN117180297B (zh) * 2023-09-08 2024-09-20 广州医科大学附属第一医院（广州呼吸中心） 用于前列腺癌诊断、治疗以及预后评估的标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7740850B2 (en) 2007-04-17 2010-06-22 ImClone, LLC PDGFRβ-specific antibodies
PL2274008T3 (pl) 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
AU2012289865A1 (en) * 2011-08-03 2014-02-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide compounds for treating hearing and balance disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL DEATH AND DISEASE, vol. 5, no. 10, JPN7020000269, 2014, pages 1506, ISSN: 0004346893 *
CIRCULATION, vol. vol.130，no.suppl.2，abstract 18576, JPN7020000268, 2014, ISSN: 0004346892 *

Also Published As

Publication number Publication date
CA2980385A1 (en) 2016-09-29
EP3271458A1 (en) 2018-01-24
WO2016150870A1 (en) 2016-09-29
US20180044672A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
JP2018517660A (ja) 周皮細胞長鎖非コーディングｒｎａ
Duan et al. MicroRNA‐214 is upregulated in heart failure patients and suppresses XBP1‐mediated endothelial cells angiogenesis
CN107075515B (zh) C/EBPα组合物和使用方法
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
CN107108685A (zh) miR‑29模拟物及其用途
US20180023080A1 (en) Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
EP2454370A1 (en) Microrna-24
Zhou et al. Targeting RPTPσ with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model
US20240117358A1 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding rna overlapping the lck gene that regulates prostate cancer cell growth
WO2013165320A1 (en) Treating cancer by increasing expression of socs6
CN102433383B (zh) 人stim1基因的用途及其相关药物
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
CN104928353A (zh) 人dgkz基因的用途及其相关药物
Cui et al. MicroRNA-92a-3p regulates retinal angiogenesis by targeting SGK3 in vascular endothelial cells
CN105779576A (zh) 人tnfrsf12a基因的用途及其相关药物
US12319967B2 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US20240068037A1 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding rna overlapping the lck gene that regulates prostate cancer cell growth
US20220186228A1 (en) Synthetic microrna mimics
CN105803053B (zh) 人rbm17基因的用途及其相关药物
US20190381125A1 (en) Methods of Treating Angiogenesis-Related Disorders Using JNK3 Inhibitors
JP7097606B2 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、がん細胞増殖抑制剤、医薬、及びｓｐｏｎ１－ｔｒｉｍ２９融合遺伝子の利用
EP2586453A1 (en) Tumor growth controlling method targeting galactosylceramide expression factor-1
CN106267208A (zh) Rps15a基因的用途及其相关药物
WO2024003350A1 (en) Combination therapy for melanoma
CN121243391A (en) Application of THBS4 inhibitor in preparation of medicines for preventing and/or treating pulmonary arterial hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200915